Education
About Us
Working with TipRanks
Follow Us
Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
BDRX Stock Chart & Stats
$2.33
$0.02(0.46%)
At close: 4:00 PM EST
$2.33
$0.02(0.46%)
Day’s Range― - ―
52-Week Range$0.90 - $44.40
Previous CloseN/A
Volume6.04K
Average Volume (3M)260.97K
Market Cap
$585.39K
Enterprise Value-$2.96M
Total Cash (Recent Filing)$4.04M
Total Debt (Recent Filing)$501.00K
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Apr 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding838,787
10 Day Avg. Volume685,915
30 Day Avg. Volume260,967
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-5.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.60
Enterprise Value/Ebitda0.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$7.66K
Bulls Say, Bears Say
Bulls Say
Phase 3 Trial EnrollmentThe enrollment in a Phase 3 trial for eRapa marks a significant milestone, potentially leading to the first non-surgical treatment for familial adenomatous polyposis, addressing a $7 billion market. This progress could enhance Biodexa's market position and revenue potential.
First Mover AdvantageBeing the first mover in developing a non-surgical treatment for FAP provides Biodexa with a competitive edge, potentially capturing significant market share and establishing a leadership position in this therapeutic area.
Grant Funding SupportThe $20 million grant from CPRIT supports Biodexa's Phase 3 trial, reducing financial strain and enabling continued R&D efforts. This funding enhances the company's ability to advance its pipeline without immediate reliance on additional equity or debt financing.
Bears Say
Declining RevenueThe consistent decline in revenue over recent years highlights challenges in product commercialization and market penetration, potentially impacting long-term growth and sustainability if not addressed.
Negative Profit MarginsNegative profit margins suggest inefficiencies in cost management and pricing strategy, which could hinder profitability and limit resources for reinvestment in R&D and market expansion.
Cash Flow ChallengesPersistent negative operating cash flow indicates ongoing cash burn, which may necessitate additional financing to sustain operations, potentially diluting shareholder value or increasing debt burden.
Biodexa Pharmaceuticals News
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $0.90 and its highest was $44.40 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is $585.39K.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Apr 24, 2026 which is in 49 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Sep 12, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.004 by $0.004.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Overvalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 838,787 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of $0 in its last earnings report, beating expectations of -$0.004. Following the earnings report the stock price went up 1.518%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Technical Analysis
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
Enveric Biosciences
―
CNS Pharmaceuticals
―
Ownership Overview
―
Insiders
34.66% Other Institutional Investors
65.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---